Drug Trial Radar · NCT07909070
A Study to Investigate the Pharmacokinetics of JMKX003142 in Healthy Participants and Participants With Hepatic Impairment
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Nov 20, 2026
Primary completion
May 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- JemincareIndustry
- Sponsor type
- Industry
- Collaborators
- Zhejiang Hangyu Pharmaceutical Co., Ltd.
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the plasma PK of JMKX003142 following a single dose in participants with mild and moderate hepatic impairment compared to matched healthy participants with normal hepatic function.
Conditions
- ADPKD (Autosomal Dominant Polycystic Kidney Disease)
- Renal Edema
Interventions
JMKX003142Drug
Single oral dose of JMKX003142 in participants from all groups
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK parameter CmaxTime frame: Predose up to 6 days postdose
- PK parameters AUC0-tTime frame: Predose up to 6 days postdose
- PK parameters AUC0-infTime frame: Predose up to 6 days postdose
- PK parameters Cmax, uTime frame: Predose up to 6 days postdose
- PK parameters AUC0-t, uTime frame: Predose up to 6 days postdose
- PK parameters AUC0-inf, uTime frame: Predose up to 6 days postdose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.